Encouraging HIV/AIDS vaccine trial results support GeoVax strategy.GeoVax Labs, Inc. (Atlanta, GA), a biopharmaceutical company developing human vaccines for HIV/AIDS (HIV-1, Human Immunodeficiency Virus human immunodeficiency virus
Human immunodeficiency virus (HIV)
A transmissible retrovirus that causes AIDS in humans. ), spoke about a partial success in the recently completed Phase 3 trial in Thailand of a candidate HIV/AIDS vaccine owned by Sanofi-Aventis and Global Solutions for Infectious Diseases. The completed study represents the first HIV/AIDS vaccine trial to show prevention of infection.
Robert McNally, Ph.D., Chief Executive Officer and President stated, "The results are highly encouraging for the clinical studies of our HIV/AIDS vaccine and we congratulate the Thai ministry of Public Health for successful conduct of a groundbreaking trial that included 16,000 volunteers and was supported by multiple agencies including the United States Army United States Army
Major branch of the U.S. military forces, charged with preserving peace and security and defending the nation. The first regular U.S. fighting force, the Continental Army, was organized by the Continental Congress on June 14, 1775, to supplement local and the United States National Institutes of Health (NIH "Not invented here." See digispeak.
NIH - The United States National Institutes of Health. )."
"The partial success of this trial is very important to the GeoVax vaccine, because the vaccine tested in Thailand, like the GeoVax vaccine, was designed to elicit both T cells and antibody," said Dr. Harriet Robinson, Senior Vice President of Research & Development. "The two vaccines that have failed in previous efficacy trials elicited only antibody or only T cells. This was the first efficacy test of a vaccine that elicited both antibody and T cells and is very encouraging for the GeoVax vaccine, because our vaccine generates higher frequencies of T cells and better quality antibody. Given what we know about the elicited responses observed in this study, and the similarities and differences between our vaccine and the Sanofi-Aventis vaccine, the GeoVax vaccine should be poised for a higher level of protective success than the 30% success rate achieved in Thailand," noted Dr. Robinson.
"Within the two main areas of focus for our HIV/AIDS vaccine--preventative and therapeutic--we continue to make progress," stated Dr. McNally. "The preventative version of the vaccine has advanced to a Phase 2a human clinical trial, which was initiated in February 2009 by the HIV Vaccine Trials Network The HIV Vaccine Trials Network is a collaboration between physicians, scientists and activists that conducts clinical trials seeking a safe and effective HIV vaccine. They review potential vaccines for safety, immune response and efficacy. (HVTN) and continues to have steadily increasing enrollment. On the therapeutic vaccine, we continue to plan out the details of a Phase 1 human clinical trial and expect to begin this trial, assuming United States Food and Drug Administration United States Food and Drug Administration (FDA),
n.pr a unit of the Public Health Service created to protect the health of the nation against impure and unsafe foods, drugs, and cosmetics. (FDA) concurrence, in the first quarter of 2010."
GeoVax's unique two component vaccine, a recombinant DNA and a recombinant modified vaccinia Ankara (MVA MVA
motor vehicle accident
MVA Motor vehicular/vehicle accident, see there ), is designed to stimulate both anti-HIV T cell and anti-HIV antibody immune responses. GeoVax's DNA DNA: see nucleic acid.
or deoxyribonucleic acid
One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. and MVA vaccines are used in a prime-boost protocol in which priming is done with the DNA and boosting with the MVA. GeoVax is also investigating a potentially simpler regimen in which MVA is used for both priming and boosting. Both the DNA and MVA express the three major proteins of the AIDS virus: Gag, Pol, and Env, and produce non-infectious virus-like-particles. These particles contain proteins that mimic more than half of the components of the AIDS virus, but cannot cause AIDS. This multi-protein approach is designed to elicit a broad multi-target protective T cell response. The Env protein is designed to elicit a protective antibody response against the natural form of the virus envelope glycoprotein as well as protective T cells.
"One of the strong features of our vaccines is their stability during manufacture," said Dr. Robinson. "During development, we and our collaborators at the National Institutes of Health persevered to construct vaccines that showed solid stability under commercial manufacturing conditions. We did not advance a vaccine until we had demonstrated stability. We have available inventory and can readily contract manufacture additional product," added Dr. Robinson.
HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. affects the entire globe and comes in a variety of subtypes. Clade B is the predominant subtype in North America, where there are roughly 60,000 new infections each year. Globally, there are about 2.5 million AIDS infections per year, most primarily involving subtypes AG, B, and C. In 2007, UNAIDS reported 1.3 million people living with AIDS in North America and 33.2 million people living with AIDS worldwide. Whereas the Thai trial was conducted with a vaccine targeted for infections endemic to Thailand; the GeoVax vaccine is targeted for the "clade B" type of HIV-1 prevalent in the Americas, Europe and Australia.
GeoVax is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's AIDS vaccine technology is the subject of 20 issued or filed patent applications. GeoVax AIDS vaccines are designed for use in uninfected people to prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person become infected. GeoVax AIDS vaccines also may be effective as a therapeutic treatment (for people already infected with the HIV-1 virus).
GeoVax's core AIDS vaccine technologies were developed by Dr. Harriet Robinson, Senior V.P. of Research and Development, through a collaboration of colleagues at Emory University's Vaccine Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention Centers for Disease Control and Prevention (CDC), agency of the U.S. Public Health Service since 1973, with headquarters in Atlanta; it was established in 1946 as the Communicable Disease Center. (CDC) and GeoVax.
GeoVax's AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN)(Seattle, WA) The HVTN, funded through a cooperative agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials program dedicated to the development and testing of AIDS vaccines. Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID NIAID National Institute of Allergy and Infectious Diseases. , which provided additional support to GeoVax AIDS vaccine development program with a $17 million IPCAVD grant awarded in late 2007.
GeoVax Labs, Inc.